A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate-Reference-Cited by-同舟云学术

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

Published:1999-01-28 Issue:4 Volume:340 Page:253-259
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Weinblatt Michael E.,Kremer Joel M.,Bankhurst Arthur D.,Bulpitt Ken J.,Fleischmann Roy M.,Fox Robert I.,Jackson Christopher G.,Lange Mary,Burge Daniel J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJM199901283400401

Cited by 1694 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Etanercept ameliorates chronic mild stress-induced depressive-like behavior in rats: Crosstalk between MAPK and STAT3 pathways and norepinephrine and serotonin transporters;European Journal of Pharmacology;2024-09

2. TIPE2 gene transfer ameliorates aging-associated osteoarthritis in a progeria mouse model by reducing inflammation and cellular senescence;Molecular Therapy;2024-09

3. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease;Annals of the Rheumatic Diseases;2024-07-04

4. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26

5. Study on the Mechanism of the Combination of Methotrexate and Leflunomide in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology, Molecular Docking, and in vitro Experimental Verification;Combinatorial Chemistry & High Throughput Screening;2024-06-20